CN101590051B - Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor - Google Patents
Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor Download PDFInfo
- Publication number
- CN101590051B CN101590051B CN2008101139162A CN200810113916A CN101590051B CN 101590051 B CN101590051 B CN 101590051B CN 2008101139162 A CN2008101139162 A CN 2008101139162A CN 200810113916 A CN200810113916 A CN 200810113916A CN 101590051 B CN101590051 B CN 101590051B
- Authority
- CN
- China
- Prior art keywords
- content
- nicotinic acid
- pharmaceutical composition
- acarbose
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title claims abstract description 213
- 229960003512 nicotinic acid Drugs 0.000 title claims abstract description 116
- 235000001968 nicotinic acid Nutrition 0.000 title claims abstract description 116
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 116
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 title claims abstract description 21
- 239000003888 alpha glucosidase inhibitor Substances 0.000 title claims abstract description 21
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 20
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 20
- 239000000890 drug combination Substances 0.000 title abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 13
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 74
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 59
- 229960002632 acarbose Drugs 0.000 claims description 47
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 47
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 26
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 claims description 23
- 229960001729 voglibose Drugs 0.000 claims description 23
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 22
- 229960001110 miglitol Drugs 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000003826 tablet Substances 0.000 claims description 22
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 21
- 229960002855 simvastatin Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 20
- 229960001770 atorvastatin calcium Drugs 0.000 claims description 18
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 14
- 229960003765 fluvastatin Drugs 0.000 claims description 14
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 14
- 229950009116 mevastatin Drugs 0.000 claims description 14
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 14
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 13
- 229960004844 lovastatin Drugs 0.000 claims description 13
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 13
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 13
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 13
- 238000013270 controlled release Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 229960002797 pitavastatin Drugs 0.000 claims description 11
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 11
- 229960000672 rosuvastatin Drugs 0.000 claims description 11
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 11
- 229960001495 pravastatin sodium Drugs 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 239000007919 dispersible tablet Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 239000007950 delayed release tablet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000003405 preventing effect Effects 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 42
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000002671 adjuvant Substances 0.000 description 17
- -1 polyoxyethylene Polymers 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 206010001580 Albuminuria Diseases 0.000 description 11
- 239000001856 Ethyl cellulose Substances 0.000 description 11
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 11
- 229920001249 ethyl cellulose Polymers 0.000 description 11
- 235000019325 ethyl cellulose Nutrition 0.000 description 11
- 208000006750 hematuria Diseases 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 125000002057 carboxymethyl group Chemical class [H]OC(=O)C([H])([H])[*] 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 230000001476 alcoholic effect Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 229920003081 Povidone K 30 Polymers 0.000 description 6
- 125000000627 niacin group Chemical group 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 239000004925 Acrylic resin Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 4
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 229960005370 atorvastatin Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 229960002965 pravastatin Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003361 porogen Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 229940086293 acarbose 100 mg Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical class CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940022682 acetone Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 description 1
- 229960001826 dimethylphthalate Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- BAZVSMNPJJMILC-UHFFFAOYSA-N triadimenol Chemical compound C1=NC=NN1C(C(O)C(C)(C)C)OC1=CC=C(Cl)C=C1 BAZVSMNPJJMILC-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Abstract
The invention relates to a drug combination containing pharmaceutic dose of nicotinic acid, pharmaceutic dose of HMG-CoA reductase inhibitor, alpha-glucosidase inhibitor and carrier which can be accepted by pharmaceutics and an application of the combinaiton in preparing medicines for preventing or treating diabetes and diabetic nephropathy. The effect of the medicines prepared with the combination provided by the invention is better than single-agent in preventing or curing diabetes and diabetic nephropathy and the medicines are easier for patients to take.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains nicotinic acid, HMG-CoA reductase inhibitor, alpha-glucosidase inhibitor and pharmaceutics acceptable carrier, and said composition is used for preventing or treating the purposes of diabetes, prevention or treatment diabetic nephropathy drugs in preparation.The invention belongs to pharmaceutical field.
Background technology
Diabetes (diabetes mellitus; DM) be the metabolism disorder that causes by Different types of etiopathogenises; Be characterized in chronic hyperglycemia; With hypoinsulinism and/or effect obstacle, cause carbohydrate, fat, protein metabolism disorder, cause chronic injury, the dysfunction depletion of multiple organ.Development along with diabetes; Under influence of various factors such as age, diabetic duration, glycemic control quality, diet control, blood pressure level, smoking and genetic predisposition; Diabetics is prone to form various vascular complications, comprises trunk complication and microvascular complication.Diabetes trunk complication is higher 2～6 times than the general population like the incidence rate that merges coronary heart disease, and the incidence rate of cerebral infarction and lower extremities than the high 3-4 of general population doubly.Diabetes microvascular complication such as kidney damage and retinopathy are especially apparently higher than the general population.Years of researches and observation show that diabetic vascular complications is one of deadly major cause of morbidity of diabetics.Hyperlipidemia is the main risk factor of type 2 diabetes mellitus trunk complication; Britain's diabetes perspective study (UKPDS) is found; In average 10 years following up a case by regular visits to, the intensive treatment group has reduced by 0.9 percentage point than conventional therapy group glycolated hemoglobin (HbAlc), causes blood capillary terminal point incident 25% (P＜0.01) that descended; But the macroangiopathic incident does not have obvious minimizing, the incidence rate of M (P=0.052) on a declining curve.Can better controlling blood glucose can reduce microangiopathic complication, but prevent coronary heart disease still uncertain.
(nicotinic acid NA) belongs to vitamin B group to nicotinic acid, is the cofactor in a kind of internal metabolism process.Heavy dose of nicotinic acid can have tangible blood lipid regulation effect.It is generally acknowledged after nicotinic acid is converted into cigarette phthalein amine in vivo and bring into play pharmacological action, the latter is nadide and coenzyme II ingredient, participates in the body lipid metabolism, the process that the oxidizing process of Tissue respiration and sugared anaerobic are decomposed.Nicotinic acid also can reduce the utilization of coenzyme A: through suppressing proteic synthetic the synthetic of cholesterol that influence of extra-low density, heavy dose still can reduce the concentration of serum cholesterol and triglyceride, and the peripheral vasodilation effect is arranged.Internal and external test proof nicotinic acid has the effect of direct inhibition cell steatolysis, causes that blood plasma free fatty acid (FFA) level sharply reduces (＞10 times).FFA is the raw material of the synthetic TG of liver, and FFA reduces, and influence synthetic TG of liver and VLDL, and VLDL is the predecessor of LDL, so nicotinic acid reduction serum TG and VLDL level also cause the reduction of LDL level.
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor is called for short Statins (statins) medicine; It is the rate-limiting enzyme that acts on liver synthesis cholesterol specifically; Can make the synthetic minimizing of cholesterol; Low density lipoprotein, LDL (LDL) receptor active strengthens, and LDL removes increase in the serum thereby make, the effect that improves HDL-C (HDL-C) simultaneously in addition and reduce triacylglycerol (TC).
The alpha-glucosidase inhibitor full name is an alpha-glucosidase inhibitor; It is one type of hyperglycemia medicine with unique blood sugar lowering mechanism; It mainly acts on is through delaying intestinal the absorption of glucose to be reached the too high purpose of blood sugar control, and has cardiovascular protective effect.At present alpha-glucosidase inhibitor mainly contains 3 kinds of acarbose (Acarbose), voglibose (Voglibose), miglitol (Miglito 1).
Summary of the invention
The purpose of this invention is to provide a kind of at the pharmaceutical composition that has advantage aspect prevention or treatment diabetes, prevention or the treatment diabetic nephropathy.For realizing above-mentioned purpose of the present invention, the present invention adopts following technical scheme:
A kind of pharmaceutical composition is made up of the nicotinic acid of pharmaceutical dosage, the HMG-CoA reductase inhibitor of pharmaceutical dosage, the alpha-glucosidase inhibitor and the pharmaceutics acceptable carrier of pharmaceutical dosage.
In the present invention, the content of nicotinic acid is 25～1000mg, and the content of HMG-CoA reductase inhibitor is 1～80mg, and the content of alpha-glucosidase inhibitor is 10～600mg.
According to the present invention, the HMG-CoA reductase inhibitor comprises simvastatin (Simvastatin), pravastatin (Pravastatin), fluvastatin (Fluvastatin), lovastatin (Lovastatin), atorvastatin (Atovastatin), mevastatin (Mevastatin), rosuvastatin (Rosuvastatin) and Pitavastatin (Pitavastatin) etc.Wherein, lovastatin content is 2mg-80mg, and simvastatin content is 2mg-80mg; Pravastatin content is 2mg-40mg, and mevastatin content is 2mg-80mg, and fluvastatin content is 10mg-80mg; Atorvastatin content is 5mg-80mg; Cerivastatin content is 0.1mg-0.3mg, and Rosuvastatin content is 10mg-40mg, and Pitavastatin content is 1mg-10mg.
According to the present invention, alpha-glucosidase inhibitor comprises acarbose, voglibose and miglitol etc.Wherein, acarbose content is that 25mg-600mg, voglibose content are that 0.05mg-0.6mg, miglitol content are 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, simvastatin and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of simvastatin is 1mg-15mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, pravastatin sodium and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of pravastatin sodium is 2mg-10mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, fluvastatin and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of fluvastatin is 2mg-20mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, lovastatin and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of lovastatin is 3mg-20mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, Atorvastatin calcium and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of Atorvastatin calcium is 2mg-20mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, mevastatin and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of mevastatin is 10mg-40mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, rosuvastatin and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of rosuvastatin is 1mg-10mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, Pitavastatin and acarbose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of Pitavastatin is 0.5mg-4mg, and the content of acarbose is 25mg-100mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, simvastatin and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of simvastatin is 1mg-15mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, pravastatin sodium and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of pravastatin sodium is 2mg-10mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, fluvastatin and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of fluvastatin is 2mg-20mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, lovastatin and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of lovastatin is 3mg-20mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, Atorvastatin calcium and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg; The content of Atorvastatin calcium is 2mg-20mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, mevastatin and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of mevastatin is 10mg-40mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, rosuvastatin and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of rosuvastatin is 1mg-10mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, Pitavastatin and voglibose as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of Pitavastatin is 0.5mg-4mg, and the content of voglibose is 0.05mg-0.6mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, pravastatin sodium and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of pravastatin sodium is 2mg-10mg, and the content of miglitol is 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, fluvastatin and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of fluvastatin is 2mg-20mg, and the content of miglitol is 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, lovastatin and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of lovastatin is 3mg-20mg, and the content of miglitol is 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, Atorvastatin calcium and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of Atorvastatin calcium is 2mg-20mg, and the content of miglitol is 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, mevastatin and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of mevastatin is 10mg-40mg, and the content of miglitol is 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, rosuvastatin and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of rosuvastatin is 1mg-10mg, and the content of miglitol is 25mg-300mg.
As a kind of pharmaceutical composition of the present invention; Pharmaceutical composition provided by the invention by nicotinic acid, Pitavastatin and miglitol as active component; Wherein the content of nicotinic acid is 25mg-1000mg, and the content of Pitavastatin is 0.5mg-4mg, and the content of miglitol is 25mg-300mg.
Term " pharmaceutical dosage " is meant that the clinician grants the dosage of medicine to diseased individuals according to the diseased individuals degree that is in a bad way in order to reach effective treatment, prevent or to delay the purpose of disease.Be to be understood that medicine pharmaceutical dosage provided by the invention is not a limitation of the present invention, but to of the present invention preferred.Generally, in this dosage preferable range, this medicine can produce efficacious therapy, prevents or delay effect to disease that the patient takes a disease.Diseased individuals is meant the self-existent life entity of suffering from disease, and in the present invention, life entity refers to the mankind especially.Should be appreciated that in the prior art, human pharmaceutical use dosage or pharmaceutical dosage scope can with mammal, like rat, mice etc., converting is fit to pharmaceutical dosage or the dosage range that corresponding animal is suitable for to draw.
According to the present invention; Active component in the pharmaceutical composition is the solvent in the compositions; One of them active component comes from nicotinic acid, a kind of from HMG-CoA reductase inhibitor or its officinal salt of second active component, and the 3rd active component is from alpha-glucosidase inhibitor.The dosage form of this pharmaceutical composition include but not limited to conventional tablet, bilayer tablet, multilayer tablet, slow releasing tablet, single chamber controlled release tablet, two chambers controlled release tablet, pore type controlled release tablet, sublingual lozenge, oral cavity quick disintegrating slice, dispersible tablet, enteric coatel tablets, granule, pill, enteric coated capsule, delayed-release tablet, regularly/position releasing piece, conventional capsule, slow releasing capsule, controlled release capsule, contain micropill or small pieces capsule, contain pH dependent form capsule, oral liquid, membrane or the patch of micropill or small pieces; What should particularly point out is that the pharmaceutical composition that will contain nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor is processed tablet or capsule.
Also contain the pharmaceutics acceptable carrier in this pharmaceutical composition; Can be made into common oral preparation; Comprise conventional tablet, conventional capsule, granule etc.; Said pharmaceutics acceptable carrier includes excipient and the adjuvant that helps reactive compound is mixed with pharmaceutical formulation when processing tablet, and the compositions like one or more materials of starch, sucrose, dextrin, microcrystalline Cellulose, inorganic salts, lactose, sodium chloride, citric acid and sodium sulfite etc. belongs to this area general knowledge.
Also contain the pharmaceutics acceptable carrier in this pharmaceutical composition, can be made into slow releasing preparation, comprise excipient and adjuvant etc.Described excipient and adjuvant have comprised that the adjuvant of slow releasing function is that solubility/insoluble salt and/or ethyl cellulose and/or other of hydroxypropyl methylcellulose and/or ethyl cellulose and/or polyacrylic resin class and/or polycarboxy ethene and/or alginic acid play the adjuvant of slow releasing function; The hypromellose employing includes the extensive stock of hydroxypropyl methylcellulose (HPMC) such as U.S. many elegant (Methocel) of all size; Ethyl cellulose adopts the extensive stock that includes ethyl cellulose (EC), and polyacrylic resin adopts the acrylic resin (Eudragit) that includes polyacrylic resin II, III class or analog such as all size.
Also contain the pharmaceutics acceptable carrier in this pharmaceutical composition, can be made into controlled release preparation, comprise that active medicine has reached the adjuvant of controlled release effect.The above-mentioned adjuvant that plays the controlled release effect is polyoxyethylene and/or hypromellose and/or ethyl cellulose and/or sodium chloride and/or lactose and/or mannitol and/or fructose and/or glucose and/or sucrose or low-substituted hydroxypropyl cellulose and/or cross-linking sodium carboxymethyl cellulose and/or crospolyvinylpyrrolidone and/or cellulose acetate.Above-mentioned adjuvant is pharmaceutical carrier, expanding material, permeation-promoter, solubilizing agent, binding agent, wetting agent, lubricant, coloring agent, porogen, membrane material, antiplastering aid, plasticizer, lucifuge agent, solvent.Pharmaceutical carrier, expanding material can adopt polyoxyethylene, hypromellose, ethyl cellulose, hydroxypropyl cellulose, methylcellulose, Compritol 888 ATO class etc.; Permeation-promoter can adopt sodium chloride, lactose, mannitol etc.; Solubilizing agent can be adopted sodium lauryl sulphate or poloxamer etc.; Binding agent can adopt polyvinylpyrrolidone, hypromellose, chitosan, sodium alginate, methylcellulose, ethyl cellulose, starch slurry, arabic gum, gelatin, sucrose, polyvinyl alcohol etc.; Wetting agent can adopt the ethanol-water solution of dehydrated alcohol, water, various concentration; Lubricant can adopt stearic acid, magnesium stearate, Pulvis Talci, starch, paraffin etc.; Coloring agent can adopt natural pigment such as carmine, amaranth, lemon yellow, bright orchid, indigo, brownish red ferrum oxide and synthetic dyestuff or the like; Porogen can adopt sucrose, mannitol, Polyethylene Glycol, titanium dioxide, Pulvis Talci, silicon dioxide etc.; Membrane material can adopt cellulose acetate, ethyl cellulose, hydroxypropyl emthylcellulose acetic acid succinate, beautiful jade Cellulose Acetate Phthalate, gather phthalic acid vinyl acetate cellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose etc.; Solvent can adopt acetone, dehydrated alcohol, ethanol, water etc.
Also contain the pharmaceutics acceptable carrier in the said composition, can be made into sublingual lozenge, oral cavity quick disintegrating slice or dispersible tablet etc.; Comprise excipient and adjuvant etc.Described excipient and adjuvant have mannitol, sorbitol, maltose alcohol, low substituted hydroxy-propyl methylcellulose, microcrystalline Cellulose, carboxymethyl starch sodium, cross-linked carboxymethyl cellulose sodium, crospolyvinylpyrrolidone, processing agar, cyclodextrin, glycyrrhizic acid, stevioside, citric acid, Oleum menthae, eucalyptus oil, Oleum Caryophylli, Fructus Citri Limoniae oil, citrus seed oil and some other correctives that wraps up with microcapsule etc.
Also contain the pharmaceutics acceptable carrier in this pharmaceutical composition; Can be made into slow releasing capsule, controlled release capsule; The capsule that contains micropill or small pieces; Contain the pH dependent form capsule of micropill or small pieces etc.; Comprise excipient and adjuvant; Described excipient and adjuvant have the compositions of one or more materials of solubility/insoluble salt, octadecanol, stearic acid, sodium chloride, cysteine, citric acid and the sodium sulfite etc. of starch, microcrystalline Cellulose, inorganic salts, hydroxypropyl emthylcellulose, ethyl cellulose, polyacrylic resin class, polycarboxy ethene, alginic acid, and coating material comprises: Lac, cellulose acetate phthalate ester, ethyl cellulose, hydroxypropyl emthylcellulose, hydroxypropyl cellulose, crylic acid resin (like Eudragit L and S type etc.), polyvinyl acetate phthalic acid ester, phthalic acid hypromellose ester, succinic acid acetic acid hydroxypropyl methylcellulose, polyvinyl acetate phthalic acid ester and plasticizer (like the acetylated monoglycerides of diethyl phthalate, Polyethylene Glycol, propylene glycol, glycerol triacetate, dimethyl phthalate, dibutyl sebacate, triethyl citrate, ATBC, CitroflexA-2, Oleum Ricini and percentage etc.) and porogen various medicaments adjuvants such as (like PEG6000).
Also contain the pharmaceutics acceptable carrier in this pharmaceutical composition, can be made into dosage forms such as granule, oral liquid, membrane, patch.Said pharmaceutically acceptable carrier includes excipient and the adjuvant that helps reactive compound is mixed with pharmaceutical formulation when processing the patch membrane; Like polyvinyl alcohol, Triafol T, ethylene-vinyl acetate copolymer, polyvinylpyrrolidone, polyacrylamide, polybutene class pressure sensitive adhesive, crylic acid resin pressure sensitive adhesive, silicone pressure sensitive adhesive etc.; And back lining materials such as polrvinyl chloride, polyethylene, aluminium foil, polypropylene, polyester, the compositions of one or more materials of protecting film such as polyethylene, polystyrene, polypropylene etc.
Chemical compound in the pharmaceutical composition provided by the invention can be granted diseased individuals simultaneously in identical preparation, also grant diseased individuals discriminably in succession.If grant diseased individuals in succession, then the delay of granting of second (or additional) active component should not cause active component to unite the loss of the beneficial effect that brings.If grant diseased individuals simultaneously, the chemical compound in the compositions can mix and be present in the same pharmaceutical dosage forms, also can independently exist respectively with same dosage form.If the dosage form with same independently exists respectively, then pharmaceutical composition can flexible existing with " Combined drug box " form." Combined drug box " is a kind of case type container, the drug regimen of built-in one or more dosage forms, and operation instructions.The compound tablet that a kind of and described alpha-glucosidase inhibitor in preferred in the present invention described nicotinic acid, described HMG-CoA reductase inhibitor and the officinal salt thereof is formed.
Chemical compound in the pharmaceutical composition provided by the invention can be granted diseased individuals simultaneously in preparation inequality, also grant diseased individuals discriminably in succession.If grant diseased individuals in succession, then the delay of granting of second (or additional) active component should not cause active component to unite the loss that brings beneficial effect.If grant diseased individuals simultaneously, the chemical compound in the compositions independently exists with different dosage forms, and pharmaceutical composition also can flexible existing with " Combined drug box " form." Combined drug box " is a kind of case type container, the drug regimen of built-in one or more dosage forms, and operation instructions.
The pharmaceutical composition that another object of the present invention provides alpha-glucosidase inhibitor and pharmaceutically suitable carrier of a kind of, the pharmaceutical dosage in HMG-CoA reductase inhibitor or its officinal salt of the nicotinic acid that contains pharmaceutical dosage, pharmaceutical dosage is used for preventing or treating the purposes of the medicine of diabetes in preparation.
The pharmaceutical composition that another object of the present invention provides alpha-glucosidase inhibitor and pharmaceutically suitable carrier of a kind of, the pharmaceutical dosage in HMG-CoA reductase inhibitor or its officinal salt of the nicotinic acid that contains pharmaceutical dosage, pharmaceutical dosage is used for preventing or treating the purposes of diabetic nephropathy drugs in preparation.
In all purposes provided by the invention; The HMG-CoA reductase inhibitor is selected from a kind of in simvastatin, pravastatin, fluvastatin, lovastatin, atorvastatin, mevastatin, rosuvastatin and the Pitavastatin, preferred atorvastatin, simvastatin.
In all purposes provided by the invention, alpha-glucosidase inhibitor is selected from acarbose, voglibose and miglitol, preferred acarbose.
Advantage of the present invention is:
The invention provides the pharmaceutical composition of HMG-CoA reductase inhibitor, alpha-glucosidase inhibitor and pharmaceutically suitable carrier of the nicotinic acid that contains pharmaceutical dosage, pharmaceutical dosage.The combined effect of nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor be not each active substance each self-applying simply add and, but have more significant effect aspect treatment or prevent diabetes and the diabetic complication.That is to say that nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor administering drug combinations have been obtained synergy.Pharmaceutical composition provided by the invention has remarkable advantages on the therapeutic effect of blood sugar lowering, and has the beneficial effect of tangible prevent diabetes complication, is treatment or prevent diabetes and diabetes complicated disease drug preferably therefore.
Below in conjunction with the specific embodiment the present invention being further specified, is not to qualification of the present invention, all any this areas of carrying out according to content of the present invention be equal to replacement, all belong to protection scope of the present invention.
The specific embodiment
The consumption of the preparation process of following pharmaceutical preparation embodiment and used material of preparation or the used material of preparation is not limited to character express; All formulation methods that contains pharmaceutical composition provided by the invention; All belong to protection scope of the present invention; But concrete experimental technique reference drug preparation quick-reference book is like " pharmaceutical necessities is used and preparation ", " pharmaceutics ", " Biopharmaceutics and Pharmacokinetics " etc.
Embodiment 1: preparation compound niacin simvastatin acarbose tablet (1000 amounts)
Prescription: nicotinic acid 500g
Simvastatin 5g
Acarbose 100g
Microcrystalline Cellulose 10g
Carboxymethyl starch sodium 20g
Low-substituted hydroxypropyl cellulose 20g
5% 30 POVIDONE K 30 BP/USP-30 (95% alcoholic solution) is an amount of
Magnesium stearate 1%
Method for preparing:
(1) nicotinic acid, simvastatin and the acarbose of getting recipe quantity crossed behind 100 mesh sieves subsequent use by equivalent incremental method mix homogeneously respectively;
(2) other adjuvant is crossed 100 mesh sieves respectively after, in 75 ℃ of dry about 2h;
(3) get microcrystalline Cellulose, carboxymethyl starch sodium, the low-substituted hydroxypropyl cellulose mixing of recipe quantity, then with mixed crude drug by equivalent incremental method mix homogeneously;
(4) add 5% 30 POVIDONE K 30 BP/USP-30,95% alcoholic solution and process soft material in right amount, 24 mesh sieves are granulated, 40 ℃ of dryings, and controlling particulate water content is 2-3%, 20 mesh sieve granulate;
(5) with dried granule and magnesium stearate mix homogeneously, tabletting behind the assay, aluminium-plastic bubble plate packing.
Embodiment 2: preparation compound niacin pravastatin sodium acarbose tablet (1000 amounts)
Prescription: nicotinic acid 500g
Pravastatin sodium 5g
Acarbose 100g
Microcrystalline Cellulose 10g
Carboxymethyl starch sodium 20g
Low-substituted hydroxypropyl cellulose 20g
5% 30 POVIDONE K 30 BP/USP-30 (95% alcoholic solution) is an amount of
Magnesium stearate 1%
Method for preparing: with embodiment 1.
Embodiment 3: preparation compound niacin Atorvastatin calcium voigelibo sugar-tablet (1000 amounts)
Prescription: nicotinic acid 500g
Atorvastatin calcium 10g
Voglibose 0.2g
Microcrystalline Cellulose 10g
Carboxymethyl starch sodium 20g
Low-substituted hydroxypropyl cellulose 20g
5% 30 POVIDONE K 30 BP/USP-30 (95% alcoholic solution) is an amount of
Magnesium stearate 1%
Method for preparing: with embodiment 1.
Embodiment 4: preparation compound niacin fluvastatin acarbose capsule (1000)
Prescription: nicotinic acid 500g
Fluvastatin 10g
Acarbose 100g
Lactose 100～200g
Carboxymethyl starch sodium 15～25g
5% 30 POVIDONE K 30 BP/USP-30 (95% alcoholic solution) is an amount of
Magnesium stearate 1%
Method for preparing: supplementary material was pulverized 80 mesh sieves, drying for standby.The nicotinic acid, fluvastatin, acarbose of getting recipe quantity add 100～200g lactose, 15～25g carboxymethyl starch sodium (the definite consumption of adjuvant is according to the adjustment of active medicine consumption), according to equivalent incremental method uniform mixing according to equivalent incremental method mix homogeneously; Process soft material with 10% polyvidone alcoholic solution, 20 mesh sieves are granulated, 60 ℃ of dry about 2h; 20 mesh sieve granulate, controlling particulate water content is 2-3%, with dried granule and recipe quantity magnesium stearate mix homogeneously; Semi-finished product detect; Measure content, the Capsules of packing into promptly gets 1000 capsules.Note lucifuge in the preparation process.The qualified back of product inspection aluminium-plastic bubble plate packing keeps in Dark Place.
Embodiment 5: preparation compound niacin lovastatin acarbose capsule (1000)
Prescription: nicotinic acid 500g
Lovastatin 8g
Acarbose 100g
Lactose 100～200g
Carboxymethyl starch sodium 20g
5% 30 POVIDONE K 30 BP/USP-30 (95% alcoholic solution) is an amount of
Magnesium stearate 1%
Method for preparing: with embodiment 4.
Embodiment 5: preparation compound niacin mevastatin miglitol granule
Prescription: nicotinic acid 500g
Mevastatin 8g
Miglitol 25g
Lactose 850～950g
Carboxymethyl starch sodium 10～20g
Arabic gum 2g
10% polyvidone aqueous solution is an amount of
Orange flavor 2g
Aspartame 5g
Polyethylene Glycol 1%
Method for preparing: supplementary material was pulverized 80 mesh sieves, drying for standby.The nicotinic acid, mevastatin, miglitol of getting recipe quantity add 850～950g lactose, 10～20g carboxymethyl starch sodium (the definite consumption of adjuvant is according to the adjustment of active medicine consumption), according to equivalent incremental method uniform mixing according to equivalent incremental method mix homogeneously; Process soft material with 10% polyvidone alcoholic solution, 18 mesh sieves are granulated, 60 ℃ of dry about 2h; 16 mesh sieve granulate; Controlling particulate water content is below 2%, and with dried granule and recipe quantity orange flavor, aspartame, magnesium stearate mix homogeneously, semi-finished product detect; Measure content, the aluminum bag of packing into promptly gets 1000 bags.Note lucifuge in the preparation process.
Embodiment 6: nicotinic acid Atorvastatin calcium acarbose compositions is to the influence of blood glucose in diabetic rats
90 Wistar male rats give normal diet and feed, and the tail vein is got blood behind the 10d, measures fasting blood sugar.Choose fasting blood sugar less than 88 of the rats of 7.8mmol/L, randomly draw 15 rats as the blank group.All the other rats stop eating behind the 24h; All, recover normal feeding, measure fasting blood sugar after continuing to raise 10d by 0.3g/kg intraperitoneal injection alloxan normal saline solution 1 time; Therefrom choose 60 of the diabetes rat of blood glucose value between 11.1～16.8mmol/L; Be divided into 4 groups at random, i.e. model group, nicotinic acid+Atorvastatin calcium group, acarbose group and nicotinic acid+Atorvastatin calcium+acarbose group, 15 every group.Blank group, model group rat are pressed 10ml/kg and irritate 1 physiology saline solution of clothes every days; Nicotinic acid+Atorvastatin calcium group rat is irritated clothes nicotinic acid 100mg/kg Atorvastatin calcium 10mg/kg 1 time every day; Acarbose group rat is irritated clothes acarbose 100mg/kg 1 time every day; Nicotinic acid+Atorvastatin calcium+acarbose group filling every day clothes nicotinic acid 100mg/kg, Atorvastatin calcium 10mg/kg and acarbose 100mg/kg.Broken end was got blood after each organized survival rats administration 15d, measured blood glucose value once more.Blood glucose value adopts the ortho-aminotoluene method of improvement to measure.
Table 1 nicotinic acid Atorvastatin calcium acarbose compositions is to the influence (
n=10) of diabetes rat fasting glucose
| Group | n | Dosage (mg/kg) | Blood glucose value (mmol/L) before the treatment | Treatment back blood glucose value (mmol/L) |
| The blank group | 15 | - | 5.88±1.12 | 5.86±1.07 |
| Model group | 13 | - | 12.55±1.36 ** | 12.61±1.02 ** |
| Nicotinic acid+Atorvastatin calcium group | 14 | 200 | 12.63±1.61 ** | 12.45±1.16 ** |
| The acarbose group | 14 | 100 | 12.74±1.01 ** | 8.56±1.39 ## |
| Nicotinic acid+Atorvastatin calcium+acarbose group | 15 | 200+5+100 | 12.61±1.16 ** | 6.73±1.65 ##▲▲$ |
Annotate: compare * * P＜0.01 with the blank group; Compare ##P＜0.01 with model group; Compare with nicotinic acid+Atorvastatin calcium group, ▲ ▲ P＜0.01; Compare ， $P＜0.05 with the acarbose group
Can know by table 1, compare, after the modeling of intraperitoneal injection alloxan, respectively organize the rat blood sugar value and all obviously raise (P＜0.01), show diabetes rat modeling success with the blank group.Compare with the model group rat, nicotinic acid+Atorvastatin calcium group rat blood sugar value does not have significant change, and acarbose group, nicotinic acid+Atorvastatin calcium+acarbose group rat blood sugar value then obviously reduce, and significant significant difference (P＜0.01) is arranged.Compare with the acarbose group, nicotinic acid+Atorvastatin calcium+acarbose group blood glucose value further reduces, and has compared significant difference with the acarbose group.Show that pharmaceutical composition that nicotinic acid, Atorvastatin calcium and acarbose are formed can bring into play than single medicine drug effect effect of efficacious therapy hyperglycemia more.
Embodiment 7: niacin simvastatin acarbose compositions is to the preventive effect of diabetic nephropathy rat
The rat adaptability was raised 7 days, was divided into normal control group and experimental group at random.With streptozotocin (STZ; U.S. Sigma Company products; 0.1mmol/L citrate buffer solution is made into 1% concentration, through filtering with microporous membrane sterilization, by the 60mg/kg lumbar injection) bring out the experimental group rat diabetes; Get tail blood after 72 hours and survey blood glucose, the rat of all blood glucose between 11.1～16.8mmol/L gets into the diabetes rat group.Diabetes rat is divided into 4 groups at random: model group, nicotinic acid+simvastatin group, acarbose group, nicotinic acid+simvastatin+acarbose group, 15 every group.Press dosage gastric infusion in the table 7 every day.The 12nd week behind the blood sugar increasing, got urine sample with urine analyzer detection microdose urine protein and urine erythrocyte in 24 hours after the last administration, albumin and erythrocytic number of animals appear in the calculating urine.The The above results that records is albuminuria and hematuria number of animals difference to occur between the chi-square criterion comparable group.
Table 2 niacin simvastatin acarbose compositions is to the preventive effect of diabetic nephropathy rat
| Group | n | Dosage (mg/kg) | The albuminuria number of animals appears | The hematuria number of animals appears |
| The blank group | 15 | - | 0/15 | 0/15 |
| Model group | 12 | - | 13/13 ** | 13/13 ** |
| Nicotinic acid+simvastatin group | 13 | 200 | 9/14 # | 8/14 # |
| The acarbose group | 14 | 100 | 5/12 ## | 5/12 ## |
| Nicotinic acid+simvastatin+acarbose group | 15 | 200+5+100 | 3/14 ##▲▲$ | 2/14 ##▲▲$ |
Annotate: compare * * P＜0.01 with the blank group; Compare #P＜0.05, ##P＜0.01 with model group; Compare with nicotinic acid+simvastatin group, ▲ ▲ P＜0.01; Compare ， $P＜0.05 with the acarbose group
Microdose urine protein and urine erythrocyte are that the typical case of diabetic nephropathy characterizes, so when in diabetes rat is urinated, microalbumin and erythrocyte occurring, can think that this diabetes rat suffers from diabetic nephropathy.Albuminuria and hematuria all appear in the model group diabetes rat; The rat number that albuminuria and hematuria appear in niacin simvastatin group diabetes rat is respectively 9 and 8; The rat number that albuminuria and hematuria appear in acarbose group diabetes rat is respectively 5 and 5; And appearring in niacin simvastatin acarbose group diabetes rat, the rat number of albuminuria and hematuria significantly is less than model group, niacin simvastatin group; Show that the niacin simvastatin Acarbose medicine composition has the remarkable effect of diabetes and nephropathy preventing, and preventive effect significantly is superior to the niacin simvastatin combination or the acarbose list is used.
Embodiment 8: nicotinic acid Atorvastatin calcium acarbose compositions is to the preventive effect of diabetic nephropathy rat
Experimental technique and statistical method are with embodiment 7, and medication and drug dose are seen table 3
Table 3 nicotinic acid Atorvastatin calcium acarbose compositions is to the preventive effect of diabetic nephropathy rat
| Group | n | Dosage (mg/kg) | The albuminuria number of animals appears | The hematuria number of animals appears |
| The blank group | 15 | - | 0/15 | 0/15 |
| Model group | 13 | - | 10/12 ** | 10/12 ** |
| Nicotinic acid+Atorvastatin calcium group | 13 | 50 | 7/13 ### | 8/13 ## |
| The acarbose group | 15 | 50 | 5/13 ## | 6/13 ## |
| Nicotinic acid+Atorvastatin calcium+acarbose group | 15 | 50+10+50 | 3/15 ##▲▲$$ | 4/15 ##▲▲$$ |
Annotate: compare * * P＜0.01 with the blank group; Compare ##P＜0.01 with model group; Compare with nicotinic acid+Atorvastatin calcium group, ▲ ▲ P＜0.01; Compare ， $$P＜0.01 with the acarbose group
Can find out from last table 3; Albuminuria and hematuria all appear in the 12nd all model group diabetes rats behind the blood sugar increasing; The rat number that albuminuria and hematuria appear in nicotinic acid Atorvastatin calcium group diabetes rat is respectively 7 and 8; The rat number that albuminuria and hematuria appear in acarbose group diabetes rat is respectively 5 and 6; And appearring in nicotinic acid Atorvastatin calcium acarbose group diabetes rat, the rat number of albuminuria and hematuria is respectively 3 and 4; Significantly be less than model group, nicotinic acid Atorvastatin calcium group or acarbose group, show that nicotinic acid+Atorvastatin calcium+Acarbose medicine composition has the remarkable effect of diabetes and nephropathy preventing, and preventive effect significantly is superior to the niacin simvastatin combination or the acarbose list is used.
Claims (4)
1. one kind is prevented or treatment diabetes or diabetic nephropathy drugs compositions; By the alpha-glucosidase inhibitor of the HMG-CoA reductase inhibitor of the nicotinic acid of pharmaceutical dosage, pharmaceutical dosage, pharmaceutical dosage, and pharmaceutically suitable carrier form, it is characterized in that: it is the Pitavastatin of 0.5mg-4mg that described HMG-CoA reductase inhibitor is selected from the simvastatin that content is 1mg-15mg, the pravastatin sodium that content is 2mg-10mg, the fluvastatin that content is 2mg-20mg, the lovastatin that content is 3mg-20mg, the Atorvastatin calcium that content is 2mg-20mg, the mevastatin that content is 10mg-40mg, rosuvastatin and the content that content is 1mg-10mg; Described alpha-glucosidase inhibitor is selected from the acarbose that content is 25mg-100mg, voglibose and the content that content is 0.05mg-0.6mg is the miglitol of 25mg-300mg; Described nicotinic acid content is 25mg-1000mg.
2. the described pharmaceutical composition of claim 1 is characterized in that: this pharmaceutical composition process conventional tablet, multilayer tablet, slow releasing tablet, single chamber controlled release tablet, two chambers controlled release tablet, pore type controlled release tablet, sublingual lozenge, oral cavity quick disintegrating slice, dispersible tablet, enteric coatel tablets, granule, pill, enteric coated capsule, delayed-release tablet, regularly/position releasing piece, conventional capsule, slow releasing capsule, controlled release capsule, the capsule that contains micropill or small pieces, oral liquid, membrane or patch.
3. the purposes of each described pharmaceutical composition in the medicine of preparation prevention or treatment diabetes in the claim 1 to 2.
4. each described pharmaceutical composition prevents or treats the purposes in the diabetic nephropathy drugs in preparation in the claim 1 to 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101139162A CN101590051B (en) | 2008-05-29 | 2008-05-29 | Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101139162A CN101590051B (en) | 2008-05-29 | 2008-05-29 | Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101590051A CN101590051A (en) | 2009-12-02 |
| CN101590051B true CN101590051B (en) | 2012-11-07 |
Family
ID=41405054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101139162A Active CN101590051B (en) | 2008-05-29 | 2008-05-29 | Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101590051B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054888B (en) * | 2012-12-30 | 2015-08-12 | 成都恒瑞制药有限公司 | Solid orally ingestible containing acarbose and Atorvastatin calcium and preparation method thereof |
| CN103110622A (en) * | 2013-02-04 | 2013-05-22 | 成都恒瑞制药有限公司 | Solid oral agent containing voglibose and atorvastatin calcium and preparation method thereof |
| CN112451678B (en) * | 2020-12-04 | 2022-08-02 | 首都医科大学附属北京朝阳医院 | HMG-CoA reductase inhibitor-vitamin D pharmaceutical composition and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425374A (en) * | 2003-01-20 | 2003-06-25 | 鲁南制药股份有限公司 | Composition for treating hyperlipemia |
-
2008
- 2008-05-29 CN CN2008101139162A patent/CN101590051B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425374A (en) * | 2003-01-20 | 2003-06-25 | 鲁南制药股份有限公司 | Composition for treating hyperlipemia |
Non-Patent Citations (2)
| Title |
|---|
| 王晓梅 等.不同剂量辛伐他汀治疗2型糖尿病血脂紊乱的临床观察.《大连大学学报》.2007,第28卷(第3期),78-80. * |
| 邱少慧.糖尿病血脂异常的药物治疗.《医学综述》.2007,第13卷(第1期),27-30. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101590051A (en) | 2009-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101695575A (en) | Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid | |
| CN101069745B (en) | Medicine composition for treating 2-type diabetes | |
| CN102065847A (en) | Pharmaceutical formulation containing angiotensin-II receptor blocker | |
| CN101897706A (en) | Composition containing folic acid and B vitamins and applications thereof | |
| CN103230592A (en) | Composition of statin medicine and 5-methyltetrahydrofolic acid, and application thereof | |
| CN103721261A (en) | Pharmaceutical composition containing SGLT2 (sodium-glucose type 2 transporter) inhibitors and group B vitamins as well as application thereof | |
| EP2370061B1 (en) | Pharmaceutical composition comprising ezetimibe and simvastatin | |
| CN101103993B (en) | Hypoglycemic medicine composition | |
| CN101590051B (en) | Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor | |
| CN101590052A (en) | The medical composition and its use that contains calcium ion antagonist, lipid-lowering statins and nicotinic acid | |
| EP2549982A1 (en) | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe | |
| CN101897709A (en) | Drug composition containing small dosage of folic acid and aspirin and application thereof | |
| CN101069746B (en) | Composition containing sugar-reducing medicine and antiplatelet medicine | |
| CN101590084B (en) | Pharmaceutical composition containing angiotensin converting enzyme inhibitors, B vitamins and ginkgo biloba extracts | |
| CN115518066A (en) | Pharmaceutical composition for treating anticoagulation and application | |
| CN101695492A (en) | Pharmaceutical composition containing statin-type lipid-lowering medicaments, sulphonylurea-type hypoglycemic medicaments and nicotinic acid | |
| CN101590040A (en) | The composition and use thereof that contains indopamide and vitamin B group | |
| CN101590232A (en) | The medical composition and its use of angiotensin-convertion enzyme inhibitor, lipid-lowering statins and nicotinic acid | |
| CN101590053A (en) | The pharmaceutical composition that contains nicotinic acid, statin compound and thiazolidine dione compounds | |
| CN101869567A (en) | Medicament composition containing biguanide antidiabetic medicament and sartan antihypertensive medicament and applications thereof | |
| CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition | |
| CN101869708A (en) | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof | |
| CN101590231A (en) | The medical composition and its use of Angiotensin, lipid-lowering statins and nicotinic acid | |
| CN101897711B (en) | Pharmaceutical composition containing HMG-CoA reductase inhibitor, aspirin, folic acid and nicotinic acid and applications thereof | |
| CN1969855B (en) | Pharmaceutical composition having target organ protection function and usage thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug combination containing nicotinic acid, HMG-CoA reductase inhibitor and alpha-glucosidase inhibitor Effective date of registration: 20130523 Granted publication date: 20121107 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: SHENZHEN AUSA PHARMED Co.,Ltd.|Beijng Aosa Medical Research Center, Inc. Registration number: 2013990000315 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20121107 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: SHENZHEN AUSA PHARMED Co.,Ltd.|Beijng Aosa Medical Research Center, Inc. Registration number: 2013990000315 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000315 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
| CP02 | Change in the address of a patent holder |
Address after: 100176 Beijing economic and Technological Development Zone, West Beijing Road, No. 18, block C, room 216 Co-patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Beijng Aosa Medical Research Center, Inc. Address before: 100176 room A403, 14 Zhonghe street, Beijing economic and Technological Development Zone Co-patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee before: Beijng Aosa Medical Research Center, Inc. |
|
| CP02 | Change in the address of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211228 Address after: 222069 China (Jiangsu) pilot Free Trade Zone, Lianyungang Economic and Technological Development Zone, comprehensive free trade zone, complex building 422-896 Patentee after: Jiangsu AoSA Pharmaceutical Group Co.,Ltd. Address before: 100176 room 216, block C, 18 West Ring Road, Beijing economic and Technological Development Zone, Beijing. Patentee before: Beijng Aosa Medical Research Center, Inc. Patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230515 Address after: 518057 the 1st and 2nd floors of Building 2, phase III of biological incubator, No.16, Gaoxin Zhongyi Road, central high tech Zone, Nanshan District, Shenzhen City, Guangdong Province; the east side of the 1st floor and the 2nd and 3rd floors of building 3 Patentee after: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Jiangsu AoSA Pharmaceutical Group Co.,Ltd. Address before: 222069 China (Jiangsu) pilot Free Trade Zone, Lianyungang Economic and Technological Development Zone, comprehensive free trade zone, complex building 422-896 Patentee before: Jiangsu AoSA Pharmaceutical Group Co.,Ltd. |